Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.64 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.64 |
| ▸ | DRD3 | P35462 | 1/20 | 0.64 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.64 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.58 |
| ▸ | IDO1 | P14902 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | PNMT | P11086 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nordexfenfluramine SCHEMBL29390405 | 1.00 | HTR2A (1.00) | HTR2AHTR2BHTR2CSIGMAR1SLC6A4 | |
| Nordexfenfluramine SCHEMBL30081494 | 1.00 | HTR2A (1.00) | HTR2AHTR2BHTR2CSIGMAR1SLC6A4 | |
| Nordexfenfluramine SCHEMBL30081489 | 1.00 | HTR2A (1.00) | HTR2AHTR2BHTR2CSIGMAR1SLC6A4 | |
| Nordexfenfluramine SCHEMBL44927 | 1.00 | HTR2A (1.00) | HTR2AHTR2BHTR2CSIGMAR1SLC6A4 | |
| Nordexfenfluramine SCHEMBL895637 | 1.00 | HTR2A (1.00) | HTR2AHTR2BHTR2CSIGMAR1SLC6A4 | |
| Nordexfenfluramine SCHEMBL29538965 | 0.98 | HTR2A (0.96) | HTR2AHTR2BHTR2CSIGMAR1SLC6A4 | |
| Nordexfenfluramine SCHEMBL8412627 | 0.98 | HTR2A (0.96) | HTR2AHTR2BHTR2CSIGMAR1SLC6A4 | |
| Nordexfenfluramine SCHEMBL10562287 | 0.98 | HTR2A (0.96) | HTR2AHTR2BHTR2CSIGMAR1SLC6A4 | |
| Nordexfenfluramine SCHEMBL16673896 | 0.92 | HTR2A (0.84) | HTR2AHTR2BHTR2CSIGMAR1SLC6A4 | |
| Nordexfenfluramine SCHEMBL16673917 | 0.92 | HTR2A (0.84) | HTR2AHTR2BHTR2CSIGMAR1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023214011-A1 | ENZYMATIC METHOD FOR PREPARING (R)-3-AMINO-4-ARYL-BUTANOIC ACID DERIVATIVES | ENZYMICALS AG (DE) | 2023-11-09 | — | — | WO | claimed |
| EP-4273254-A1 | ENZYMATIC METHOD FOR PREPARING (R)-3-AMINO-4-ARYL-BUTANOIC ACID DERIVATIVES | Enzymicals AG (DE) | 2023-11-08 | — | — | EP | claimed |
| EP-0875498-A2 | Process for the production of the isomers (R) and (S)-Alpha-methyl-3-(trifluoromethyl)benzeneethanamine | Alfa Chemicals Italiana S.r.l. (IT) | 1998-11-04 | — | — | EP | claimed |
| US-5808156-A | Process for the production of the isomers (R) and (S)-α-methyl-3(trifluoromethyl)benzeneethanamine | ALFA CHEMICALS ITALIANA S.P.A. (IT) | 1998-09-15 | — | — | US | claimed |
| US-12558326-B2 | Method for treating epilepsy | XENON PHARMACEUTICALS INC. (CA) | 2026-02-24 | — | — | US | disclosed |
| EP-3829558-B1 | METHOD FOR TREATING EPILEPSY | XENON PHARMACEUTICALS INC (CA) | 2024-07-03 | — | — | EP | disclosed |
| EP-3829558-B1 | METHOD FOR TREATING EPILEPSY | XENON PHARMACEUTICALS INC (CA) | 2024-07-03 | — | — | EP | disclosed |
| WO-2023214011-A1 | ENZYMATIC METHOD FOR PREPARING (R)-3-AMINO-4-ARYL-BUTANOIC ACID DERIVATIVES | ENZYMICALS AG (DE) | 2023-11-09 | — | — | WO | disclosed |
| EP-4273254-A1 | ENZYMATIC METHOD FOR PREPARING (R)-3-AMINO-4-ARYL-BUTANOIC ACID DERIVATIVES | Enzymicals AG (DE) | 2023-11-08 | — | — | EP | disclosed |
| WO-2023101866-A1 | FENFLURAMINE FOR TREATMENT OF CONDITIONS ASSOCIATED WITH SPREADING DEPOLARIZATION | ZOGENIX INTERNATIONAL LIMITED (GB) | 2023-06-08 | — | — | WO | disclosed |
| US-20220249440-A1 | MUSCLE REGENERATION PROMOTER | SATO PHARMACEUTICAL CO., LTD. (JP) | 2022-08-11 | — | — | US | disclosed |
| US-20200030260-A1 | METHOD FOR TREATING EPILEPSY | XENON PHARMACEUTICALS INC. (CA) | 2020-01-30 | — | — | US | disclosed |
| EP-0875498-A3 | Process for the production of the isomers (R) and (S)-Alpha-methyl-3-(trifluoromethyl)benzeneethanamine | Alfa Chemicals Italiana S.r.l. (IT) | 2000-07-26 | — | — | EP | disclosed |
| EP-0875498-A3 | Process for the production of the isomers (R) and (S)-Alpha-methyl-3-(trifluoromethyl)benzeneethanamine | Alfa Chemicals Italiana S.r.l. (IT) | 2000-07-26 | — | — | EP | disclosed |
| EP-0875498-A2 | Process for the production of the isomers (R) and (S)-Alpha-methyl-3-(trifluoromethyl)benzeneethanamine | Alfa Chemicals Italiana S.r.l. (IT) | 1998-11-04 | — | — | EP | disclosed |
| EP-0875498-A2 | Process for the production of the isomers (R) and (S)-Alpha-methyl-3-(trifluoromethyl)benzeneethanamine | Alfa Chemicals Italiana S.r.l. (IT) | 1998-11-04 | — | — | EP | disclosed |
| EP-0875498-A2 | Process for the production of the isomers (R) and (S)-Alpha-methyl-3-(trifluoromethyl)benzeneethanamine | Alfa Chemicals Italiana S.r.l. (IT) | 1998-11-04 | — | — | EP | disclosed |
| US-5808156-A | Process for the production of the isomers (R) and (S)-α-methyl-3(trifluoromethyl)benzeneethanamine | ALFA CHEMICALS ITALIANA S.P.A. (IT) | 1998-09-15 | — | — | US | disclosed |
| US-5808156-A | Process for the production of the isomers (R) and (S)-α-methyl-3(trifluoromethyl)benzeneethanamine | ALFA CHEMICALS ITALIANA S.P.A. (IT) | 1998-09-15 | — | — | US | disclosed |
| US-5808156-A | Process for the production of the isomers (R) and (S)-α-methyl-3(trifluoromethyl)benzeneethanamine | ALFA CHEMICALS ITALIANA S.P.A. (IT) | 1998-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200030260-A1 | METHOD FOR TREATING EPILEPSY | PNMT, HTR5A, TPH1 | HTR2A 9/4885HTR2B 110/4885HTR2C 16/4885 |
| US-20220249440-A1 | MUSCLE REGENERATION PROMOTER | MUSK, MYLK2, MYH2 | HTR2A 28/4885HTR2B 4/4885HTR2C 72/4885 |
| US-12558326-B2 | Method for treating epilepsy | PNMT, SLC6A1, CPT1B | HTR2A 239/4885HTR2B 790/4885HTR2C 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.